Provides community-based cancer care, including medical oncology, infusions, radiation therapy and specialty pharmacy services, for patients and health plans.
10-K for FY2025, filed Mar 12, 2026While we continue our original purpose of seeing our patients on a fee-for-service basis for their oncology, hematology, specialty…View ↗
TOI provides medical care on a fee-for service basis for physician services, in-house infusion, radiation, and innovative programs like…View ↗
TOI operates specialty and retail pharmacies in all 5 states through which we are capable of filling medication orders that are incidental…View ↗
Through TOI Clinical Research, LLC ("TCR"), the clinical research arm of our affiliated professional corporations, or TOI PCs, we also…View ↗
Our business is focused on caring for adult and senior populations with medical oncology and related care needs, including members of MA…View ↗
Health plans and other payors pay monthly per enrolled patient for managed cancer care; for fee-for-service care, insurers and patients are billed for care provided. Pharmacy benefit managers are billed when medications are ordered, and clinical-trial sponsors pay for procedures performed during a trial.
10-K for FY2025, filed Mar 12, 2026TOI provides medical care on a fee-for service basis for physician services, in-house infusion, radiation, and innovative programs like…View ↗
TOI offers value-based contracts to payors, including managed care organizations and other risk-bearing entities, who are interested in…View ↗
TOI operates specialty and retail pharmacies in all 5 states through which we are capable of filling medication orders that are incidental…View ↗
Through TOI Clinical Research, LLC ("TCR"), the clinical research arm of our affiliated professional corporations, or TOI PCs, we also…View ↗
Capitation revenues of the Company consist primarily of fees for medical services provided to patients by the Company under a capitated…View ↗
Fee-for Service (FFS) revenue represents revenue earned under contracts in which the Company bills and collects for medical services…View ↗
10-K for FY2025, filed Mar 12, 2026
FY2025 revenue by product or service ↗$502.7M
10-K for FY2025, filed Mar 12, 2026
$502.7M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Patient services
|
46%
FY2022: 66%
|
Patient services, FY2025
$229M Sources
|
|
|
Specialty pharmacy
Sold outright
10-K for FY2025, filed Mar 12, 2026 |
54% |
Specialty pharmacy, FY2025
$269.2M Sources
|
Sold outright |
|
Clinical trials & other
Usage-based
|
0.9%
FY2022: 2.5%
|
Clinical trials & other, FY2025
$4.6M Sources
|
Usage-based |
Managed care organizations and other payors contract for oncology care for enrolled populations. Insurers and government programs pay for fee-for-service care; patients may also pay co-pays, while pharmaceutical companies and trial administrators pay for clinical research.
10-K for FY2025, filed Mar 12, 2026TOI provides medical care on a fee-for service basis for physician services, in-house infusion, radiation, and innovative programs like…View ↗
TOI offers value-based contracts to payors, including managed care organizations and other risk-bearing entities, who are interested in…View ↗
TOI operates specialty and retail pharmacies in all 5 states through which we are capable of filling medication orders that are incidental…View ↗
Through TOI Clinical Research, LLC ("TCR"), the clinical research arm of our affiliated professional corporations, or TOI PCs, we also…View ↗
In 2025, we generated more than 46% of our revenue from patients who are covered by value-based contracts. Historically, our value-based…View ↗
No. It lost $60.6M in FY2025.
10-Q for Q3 FY2026, filed Nov 6, 2026
−$15.7MView ↗
10-Q for Q3 FY2026, filed Nov 6, 2026
Open tableView ↗
8-K, filed Nov 5, 2026
Revenue $650 to $670 million $650 to $660 millionView ↗
8-K, filed Aug 3, 2026
On July 28, 2026, The Oncology Institute, Inc., a Delaware corporation (the “Company”) filed with the Secretary of State of the State of…View ↗
Growing. Revenue grew 2.5x in 4 years, from $203M in FY2021 to $502.7M in FY2025, about 25% a year.
A broader care-management role
The latest report describes full delegation, in which the company takes on utilization management, network construction and claims adjudication in addition to providing care. The older report discussed evolving contracts to include acute-care use and non-employed oncologists.
10-K for FY2022, filed Mar 16, 2023 10-K for FY2025, filed Mar 12, 2026In 2023, we are continuing to evolve the way we structure our value-based arrangements, particularly in areas of the country where there…View ↗
In 2025, we continued to evolve the way we structure our value-based arrangements, particularly in areas of the country where there is an…View ↗
Competes with American Oncology Network, U.S. Oncology Network, OneOncology, Evolent Health, Thyme Care, and OncoHealth
10-K for FY2025, filed Mar 12, 2026The U.S. healthcare industry is generally highly competitive. We compete with large and medium-sized local and national providers of cancer…View ↗
Loading...